CN110079527A - Reduce siRNA, recombinant vector and its application of OSBPL2 gene expression - Google Patents
Reduce siRNA, recombinant vector and its application of OSBPL2 gene expression Download PDFInfo
- Publication number
- CN110079527A CN110079527A CN201910244158.6A CN201910244158A CN110079527A CN 110079527 A CN110079527 A CN 110079527A CN 201910244158 A CN201910244158 A CN 201910244158A CN 110079527 A CN110079527 A CN 110079527A
- Authority
- CN
- China
- Prior art keywords
- seq
- nucleotide sequence
- group
- shrna
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to molecular biology and gene engineering technology field, are related to a kind of siRNA, recombinant vector and its application for reducing OSBPL2 gene expression.In particular it relates to a kind of siRNA, the siRNA specifically reduces OSBPL2 gene expression.Since siRNA provided by the invention can specifically reduce OSBPL2 gene expression, so that the siRNA can be applied to the drug of preparation treatment and/or prevention breast cancer.
Description
Technical field
The invention belongs to molecular biology and gene engineering technology field, more particularly, to a kind of reduction OSBPL2 base
Because of the siRNA of expression, the corresponding shRNA of the siRNA, the DNA of the shRNA is encoded, the recombinant vector including the DNA, packet
The recombinant slow virus for including the recombinant vector, DNA, recombinant vector and recombinant lentiviral including the siRNA, shRNA, coding shRNA
The host cell of virus and their application.
Background technique
Breast cancer is one of the malignant tumour that women is common in world wide, and new hair rate and the death rate occupy all kinds of cancers
It is the first.Although China's breast cancer incidence is relatively low, large population base, overall incidence number is more, and disease incidence has on year by year
The trend risen, and age of onset is in rejuvenation trend.Breast cancer is in origin of cell, Histological Study, disease classification, clinical table
Existing, therapeutic response and metastatic potential etc. all show great complexity and heterogeneity, limit existing breast cancer and control
The validity and popularity for the treatment of method.Clinically still lack the target spot of breast cancer treatment.
Oxygen sterol binding protein 2 (Oxysterol Binding Protein Like 2, OSBPL2) encoding gene is located at
20q13.33 having 18 exons.OSBPL2 albumen is distributed in cytoplasm and nucleus.OSBPL2 is oxygen sterol binding protein
One of family member, the family are a kind of lipid within endothelial cells receptors.OSBPL2 is in combination with phosphatide, phosphoric acid, phosphatidylinositols 3- phosphorus
Acid and 25-HYDROXY CHOLESTEROL.Current study show that OSBPL2 gene is related to hearing disability.For OSBPL2 gene and mammary gland
The relationship of cancer has not been reported.
Summary of the invention
The object of the present invention is to provide for the siRNA for reducing OSBPL2 gene expression, the corresponding shRNA of the siRNA,
The DNA for encoding the shRNA, the recombinant vector including the DNA, the recombinant slow virus including the recombinant vector, including it is described
SiRNA, shRNA, the DNA for encoding shRNA, the host cell of recombinant vector and recombinant slow virus and their application.
To achieve the goals above, the first aspect of the present invention provides a kind of siRNA, and the siRNA is specifically reduced
OSBPL2 gene expression.
Of the invention focuses on providing new breast cancer treatment target, and is not limited to specific siRNA sequence, Ke Yigen
The siRNA of the target is directed to according to the various methods design of this field routine.The siRNA usually has the nucleotide of 19~27bp
Sequence.
Specifically, the nucleotide sequence of the siRNA includes at least following set of nucleotide sequence:
(1) first group of nucleotide sequence
As shown in SEQ ID NO:1 and SEQ ID NO:2, the SEQ ID NO:1 is first group of nucleotide sequence
5'-GAGCUGCUCAAACAUAAUGAA-3', the SEQ ID NO:2 are 5'-UUCAUUAUGUUUGAGCAGCUC-3'；
(2) second groups of nucleotide sequences
As shown in SEQ ID NO:3 and SEQ ID NO:4, the SEQ ID NO:3 is second group of nucleotide sequence
5'-CACUUUAAACCGUGUGGAUUA-3', the SEQ ID NO:4 are 5'-UAAUCCACACGGUUUAAAGUG-3'；
(3) third group nucleotide sequence
As shown in SEQ ID NO:5 and SEQ ID NO:6, the SEQ ID NO:5 is the third group nucleotide sequence
5'-GGGCAAAAGCGUGGAGGCGGA-3', the SEQ ID NO:6 are 5'-UCCGCCUCCACGCUUUUGCCC-3'.
Second aspect of the present invention provides a kind of shRNA, is the single stranded RNA with loop-stem structure, the nucleosides of the shRNA
Acid sequence includes at least following set of nucleotide sequence:
(1) the 5th group of nucleotide sequence
As shown in SEQ ID NO:9 and SEQ ID NO:10, the SEQ ID NO:9 is the 5th group of nucleotide sequence
5'-CCGGGAGCUGCUCAAACAUAAUGAACUCGAGUUCAUUAUGUUUGAGCAGCUCU UUUUG-3', the SEQ ID
NO:10 is 5'-AAUUCAAAAAGAGCUGCUCAAACAUAAUGAACUCGAGUUCAUUAUGUUUGAGC AGCUC-3'；
(2) the 6th groups of nucleotide sequences
The 6th group of nucleotide sequence is as shown in SEQ ID NO:11 and SEQ ID NO:12, the SEQ ID NO:11
For 5'-CCGGCACUUUAAACCGUGUGGAUUACUCGAGUAAUCCACACGGUUUAAAGUGU UUUUG-3', the SEQ ID
NO:12 is 5'-AAUUCAAAAACACUUUAAACCGUGUGGAUUACUCGAGUAAUCCACACGGUUUA AAGUG-3'；
(3) the 7th groups of nucleotide sequences
The 7th group of nucleotide sequence is as shown in SEQ ID NO:13 and SEQ ID NO:14, the SEQ ID NO:13
For 5'-CCGGGGGCAAAAGCGUGGAGGCGGACUCGAGUCCGCCUCCACGCUUUUGCCCU UUUUG-3', the SEQ ID
NO:14 is 5'-AAUUCAAAAAGGGCAAAAGCGUGGAGGCGGACUCGAGUCCGCCUCCACGCUUU UGCCC-3'.
The third aspect of the present invention provides the DNA of the coding shRNA that the second aspect of the present invention provides, the core of the DNA
Nucleotide sequence includes at least following set of nucleotide sequence:
(1) the 9th group of nucleotide sequence
The 9th group of nucleotide sequence is as shown in SEQ ID NO:17 and SEQ ID NO:18, the SEQ ID NO:17
For 5'-CCGGGAGCTGCTCAAACATAATGAACTCGAGTTCATTATGTTTGAGCAGCTCT TTTTG-3', the SEQ ID
NO:18 is 5'-AATTCAAAAAGAGCTGCTCAAACATAATGAACTCGAGTTCATTATGTTTGAGC AGCTC-3'；
(2) the tenth groups of nucleotide sequences
Described ten group of nucleotide sequence is as shown in SEQ ID NO:19 and SEQ ID NO:20, the SEQ ID NO:19
For 5'-CCGGCACTTTAAACCGTGTGGATTACTCGAGTAATCCACACGGTTTAAAGTGT TTTTG-3', the SEQ ID
NO:20 is 5'-AATTCAAAAACACTTTAAACCGTGTGGATTACTCGAGTAATCCACACGGTTTA AAGTG-3'；
(3) the 11st groups of nucleotide sequences
The 11st group of nucleotide sequence is as shown in SEQ ID NO:21 and SEQ ID NO:22, the SEQ ID NO:
21 be 5'-CCGGGGGCAAAAGCGTGGAGGCGGACTCGAGTCCGCCTCCACGCTTTTGCCCT TTTTG-3', the SEQ
ID NO:22 is 5'-AATTCAAAAAGGGCAAAAGCGTGGAGGCGGACTCGAGTCCGCCTCCACGCTTT TGCCC-3'.
The fourth aspect of the present invention provides a kind of recombinant vector, and the recombinant vector is (to be purchased from Shanghai in GV493 plasmid
Ji Kai Gene Tech. Company Limited) multiple cloning sites AgeI and EcoRI insertion as coding third aspect present invention provide volume
The recombinant vector that the DNA of code shRNA is obtained.
The fifth aspect of the present invention provides a kind of recombinant slow virus, and the recombinant slow virus is mentioned by the fourth aspect of the present invention
The recombinant vector and virus packaging 1.0 carrier of helper plasmid pHelper and virus packaging helper plasmid pHelper 2.0 of confession carry
Body cotransfection mammalian cell obtains.
The sixth aspect of the present invention provides a kind of host cell, siRNA, this hair provided including the first aspect of the present invention
The DNA of the coding shRNA of shRNA, the third aspect of the present invention offer that bright second aspect provides, the fourth aspect of the present invention
At least one of the recombinant slow virus that the recombinant vector and the fifth aspect of the present invention of offer provide.The present invention is to the host
The specific type of cell is not particularly limited, for example, 293T cell.
The seventh aspect of the present invention provides the siRNA of the first aspect of the present invention offer, the second aspect of the present invention provides
ShRNA, the recombinant vector that provides of the coding DNA of shRNA that provides of the third aspect of the present invention, the fourth aspect of the present invention and
At least one of recombinant slow virus that the fifth aspect of the present invention provides is in the preparation that preparation inhibits OSBPL2 gene expression
Application.
The eighth aspect of the present invention provides the siRNA of the first aspect of the present invention offer, the second aspect of the present invention provides
ShRNA, the recombinant vector that provides of the coding DNA of shRNA that provides of the third aspect of the present invention, the fourth aspect of the present invention and
At least one of recombinant slow virus that the fifth aspect of the present invention provides inhibits breast cancer cell growth and/or proliferation in preparation
Drug in application.
The ninth aspect of the present invention provides the siRNA of the first aspect of the present invention offer, the second aspect of the present invention provides
ShRNA, the recombinant vector that provides of the coding DNA of shRNA that provides of the third aspect of the present invention, the fourth aspect of the present invention and
At least one of recombinant slow virus that the fifth aspect of the present invention provides is in the drug of preparation treatment and/or prevention breast cancer
Application.
SiRNA provided by the invention can specifically reduce OSBPL2 gene expression, so that the siRNA can be applied to make
The standby drug treated and/or prevent breast cancer.
Other features and advantages of the present invention will then part of the detailed description can be specified.
Detailed description of the invention
Exemplary embodiment of the invention is described in more detail in conjunction with the accompanying drawings, it is of the invention above-mentioned and its
Its purpose, feature and advantage will be apparent.
Fig. 1 shows differential expression of the OSBPL2 in normal cell and breast cancer cell.Wherein, MCF-10A (is abbreviated as
It 10A) is normal cell, MCF7, MDA-MB-231 (being abbreviated as 231), T-47D and SK-BR-3 are breast cancer cell.
Fig. 2 shows strike influence of the low OSBPL2 to Cells Proliferation of Human Breast Cancer.Wherein, shCtrl is control group,
ShOSBPL2 is experimental group, and the curve of top is control group, and the curve of lower section is experimental group.
Fig. 3 shows the influence for striking low OSBPL2 to tumor-bearing mice growth of breast cancers.Wherein, NC is control group,
ShOSBPL2 is experimental group.
Specific embodiment
The preferred embodiment of the present invention is described in more detail below.Although the following describe preferred implementations of the invention
Mode, however, it is to be appreciated that may be realized in various forms the present invention without that should be limited by the embodiments set forth herein.It is real
The person that is not specified actual conditions in example is applied, is all carried out according to conventional conditions or manufacturer's recommended conditions.Agents useful for same or instrument are not
Production firm person is indicated, is the conventional products that can be obtained by commercially available purchase.
The number of source of people OSBPL2 involved in following embodiments is Gene ID:9885.
In following embodiments, statistical analysis is carried out using 6.0 software of GraphPad Prism.All experiment in vitro counterpoises
Again more than three times.Data are indicated with means standard deviation (SD).P < 0.05 is considered to have statistical significance.
Embodiment 1
The present embodiment is for illustrating that OSBPL2 high is expressed in breast cancer cell line.
The extraction of RNA and reverse transcription quantitative PCR (RT-qPCR).
1, Total RNAs extraction: the present embodiment carries out at low temperature.Cell culture carries out in 6 orifice plates, removes culture medium, PBS
1000 μ l of Trizol, shaking table 10min is added in rinsing 3 times, every hole；It is collected into 1.5ml centrifuge tube, 200 μ l chlorine are added in every pipe
It is imitative, 30sec is acutely mixed, 15min is stood, 4 DEG C of 12000rpm are centrifuged 15min；400 μ l of gentle aspiration supernatant liquid is to another new
In centrifuge tube, isometric isopropanol is added, is gently mixed by inversion, 4 DEG C of 12000rpm are centrifuged 10min；Supernatant is abandoned, 1ml is added
75% ethanol wash sediment, 4 DEG C of 12000rpm are centrifuged 10min；Supernatant is discarded as far as possible, dries 10min at room temperature, and every pipe adds
Enter 10 μ l without RNase water, dissolves, spectrophotometer is quantitative.
2, reverse transcription: every 25 μ l reverse transcription system includes 100pmol random primer, 2 μ g total serum IgEs, 1 μ of M-MLV reverse transcriptase
0.625 1.25 μ l, 5 × M-MLV buffer of μ l, dNTPs (10mM) of l, RNase inhibitor, 5 μ l, remaining uses ddH2O polishing is to 25 μ
l.Reaction condition are as follows: 37 DEG C of 1h, 95 DEG C of 5min.
3, quantitative PCR: every 20 μ l reaction system includes 2 × PCR Mix (ABI) 10 μ l, each 0.4 μ l of upstream and downstream primer,
CDNA 1 μ l, ddH2O 8.2μl.Reaction condition are as follows: 94 DEG C of 2min, 94 DEG C of 15s, 60 DEG C of 40s, 40 circulations.It is used in experiment
Primer sequence be shown in Table 1.
1 fluorescence quantitative RT-PCR primer sequence of table
Fig. 1 shows differential expression of the OSBPL2 in normal cell and breast cancer cell.Wherein, MCF-10A (is abbreviated as
It 10A) is normal cell, MCF7, MDA-MB-231 (being abbreviated as 231), T-47D and SK-BR-3 are breast cancer cell.Such as Fig. 1 institute
Show, RT-qPCR as the result is shown: in MCF7, MDA-MB-231, T-47D, SK-BR-3 breast cancer cell, OSBPL2 gene expression
Significantly (P < 0.01, P < 0.01, P < 0.01, P < 0.01) is increased relative in control group MCF-10A cell.
Embodiment 2
The present embodiment is for illustrating that striking low OSBPL2 gene expression can inhibit breast cancer to be proliferated and/or grow.
One, the preparation of RNAi slow virus clone
1, shot design
3 RNAi target sequences, OSBPL2 base are designed according to RNAi sequence design principle for OSBPL2 gene order
The nucleotide sequence of 3 kinds of siRNA of cause and the nucleotide sequence of negative control (NC).3 kinds of siRNA and negative control pair
The title answered is respectively OSBPL2-si-1a, OSBPL2-si-1b, OSBPL2-si-2a, OSBPL2-si-2b, OSBPL2-si-
3a, OSBPL2-si-3b, NC-si-a and NC-si-b are the sequence designed for negative control group.See Table 2 for details.
The nucleotide sequence of table 23 RNA disturbance target points (siRNA) and negative control
Table 3 shows the nucleotide sequence of 3 kinds of shRNA used in embodiment, and shRNA used in embodiment is OSBPL2-sh-
The nucleotides sequence of 1a, OSBPL2-sh-1b, OSBPL2-sh-2a, OSBPL2-sh-2b, OSBPL2-sh-3a, OSBPL2-sh-3b
Column, NC-sh-a and NC-sh-b are the nucleotide sequence of control group.See Table 3 for details.
The nucleotide sequence of table 33 kinds of shRNA and negative control
Table 4 shows the nucleotide sequence of the DNA of code used 3 kinds of shRNA.The DNA of the code used shRNA of embodiment is
The nucleosides of OSBPL2-d-1a, OSBPL2-d-1b, OSBPL2-d-2a, OSBPL2-d-2b, OSBPL2-d-3a, OSBPL2-d-3b
Acid sequence, NC-d-a and NC-d-b are the nucleotide sequence of control group.See Table 4 for details.
The DNA of 43 kinds of shRNA of table and the nucleotide sequence of negative control
2, carrier digestion
50 μ l digestion systems are prepared according to table 5.Various reagents are sequentially added by tab sequential, are gently blown and beaten with pipettor mixed
Even, brief centrifugation is placed in 37 DEG C of reaction 3h.Agarose gel electrophoresis is carried out to carrier digestion products, recycles purpose band.
5 carrier digestion system of table
| Reagent | Volume (μ l) |
| ddH2O | 41 |
| 10 × reaction buffer | 5 |
| The GV493 Plasmid DNA (1 μ g/ μ L) of purifying | 2 |
| AgeI(10U/μl) | 1 |
| EcoRI(10U/μl) | 1 |
| Total | 50 |
3, the DNA of shRNA anneals to form double-stranded DNA
The DNA dry powder of pairs of shRNA is dissolved in annealing buffer after synthesis, and 90 DEG C of water-bath 15min are naturally cooled to
Room temperature.
4, carrier connects
The carrier that double digestion linearizes is connected with annealing double-stranded DNA by T4DNA ligase (T4DNA ligase), 16
DEG C connection 1-3h.
6 carrier linked system of table
| Reagent | Volume (μ l) |
| Linearized vector (100ng/ μ l) | 1 |
| Double-stranded DNA (100ng/ μ l) | 1 |
| 10 × T4DNA ligase buffer solution | 2 |
| T4DNA ligase | 1 |
| Distilled water (ddH2O) | Complement to 20 |
5, it converts
10 μ L connection reaction products are added in 100 μ L competent cells, flicks and is mixed under tube wall number, placed on ice
30min；42 DEG C of heat shock 90s, ice bath are incubated for 2min；500 μ L LB culture mediums are added, are placed in 37 DEG C of shaking table shaken cultivation 1h；It takes suitable
Amount bacterium solution is uniformly coated on the plate containing corresponding antibiotic, and culture 12-16h is inverted in constant incubator.
6, sequencing identification
The positive colony transformant identified is inoculated in the LB liquid medium containing corresponding antibiotic in right amount, 37 DEG C of trainings
12-16h is supported, appropriate bacterium solution is taken to be sequenced, identified.
7, plasmid transfection and slow virus harvest
Virus packaging is related to three plasmids altogether: carrying the tool carrier plasmid GV493 carrier of target sequence (purchased from Shang Haiji
Triumphant Gene Tech. Company Limited), virus packaging 1.0 carrier of helper plasmid Helper is (purchased from the lucky triumphant limited public affairs of Gene science in Shanghai
Department) and virus packaging 2.0 carrier of helper plasmid Helper (being purchased from Shanghai Ji Kai Gene Tech. Company Limited).Using above-mentioned three
Plasmid co-transfection 293T cell.
Before transfection for 24 hours, it with the 293T cell of trypsin digestion logarithmic growth phase, is adjusted with the culture medium containing 10% serum
Cell density about 5 × 106/ 15ml is reinoculated on 10cm Tissue Culture Dish, 37 DEG C, 5%CO2Culture in incubator；For 24 hours to thin
It can be used to transfect when born of the same parents' density is up to 70%~80%；2h is changed to serum free medium before transfecting；Sterile centrifugation tube is taken, is added
Each DNA solution (20 μ g of GV493 plasmid, 1.0 pHelper vector plasmid, 15 μ g, 2.0 pHelper vector plasmid, 10 μ g), with phase
The triumphant transfection reagent of Ji of volume is answered to be uniformly mixed, adjustment total volume is 1ml, incubates 15min at room temperature；Mixed liquor is slowly added dropwise
Into 293T cell culture fluid, mix, in 37 DEG C, 5%CO2It is cultivated in cell incubator；It is discarded after culture 6h mixed containing transfection
With the culture medium of object, the PBS cleaning that 10ml is added is primary, falls after the soft transfection mixture for shaking culture dish to wash remnants
It abandons；
It is slowly added to the cell culture medium 20ml containing 10% serum, in 37 DEG C, 5%CO2Continue to cultivate 48- in incubator
72h。
8, slow virus concentration and purifying and quality inspection
According to cell state, the 293T cell supernatant of 48h (transfection can be calculated as 0h) after transfection is collected；In 4 DEG C,
4000g is centrifuged 10min, removes cell fragment；With 0.45 μm of filter filtering supernatant in 40ml ultracentrifugation pipe；Trim respectively
Ultracentrifugation pipe with vial supernatant is put into Beckman ultracentrifuge, 4 DEG C, 25000rpm by sample one by one,
It is centrifuged 2h；It after centrifugation, discards supernatant, removal as far as possible remains in the liquid on tube wall, and virus is added and saves liquid, gently repeatedly
Piping and druming is resuspended；Through after completely dissolution, after high speed centrifugation 10000rpm, 5min, supernatant being taken to dispense as required；
The key Quality Control of slow virus includes physical state detection, Sterility testing and virus titer detection.
Two, slow-virus transfection
To guarantee that gene jamming effectiveness, the present embodiment design 3 kinds of RNA disturbance target points (siRNA) for OSBPL2 gene, and
3 plasmid equal proportions for carrying different target spots are mixed and carry out slow virus packaging, so that it is guaranteed that purpose base after virus infected cell
Cause strikes reduction rate.
Cell secondary culture is into 6 orifice plates after 12-16 hours: virus liquid 0.15ml and fresh cell medium mixed,
Ratio is that 0.5ml fresh medium and 0.65 μ l polybrene (final concentration 4ng/ml) are added in 0.15ml vial supernatant；
Pre- mixed virus infection liquid is added in aim cell culture dish, and cell density is no more than 50% at this time.After being incubated overnight
It is replaced with fresh medium.
After infection 3 days, logarithmic growth phase cell carries out cell proliferation experiment.
Three, cell proliferation experiment
Above-mentioned control group and the cell in logarithmic growth phase for striking low OSBPL2 expression are subjected to pancreatin digestion, are made thin
Born of the same parents' suspension；Cell suspension (cell number is about 3000) is inoculated in 96 orifice plates, is counted respectively at the 1st day, 2 days, 3 days, 4 days, 5 days
Cell quantity is calculated, growth curve is drawn.
Fig. 2 shows strike influence of the low OSBPL2 to Cells Proliferation of Human Breast Cancer.Wherein, shCtrl is control group,
ShOSBPL2 is experimental group, and the curve of top is control group, and the curve of lower section is experimental group.As shown in Fig. 2, cell proliferation experiment
The results show that striking the expression of low OSBPL2 gene, the proliferation (P of breast cancer cell MCF7 was significantly inhibited with the 5th day on day 4
=0.021, P=0.007).
Four, human breast cancer in nude mice lotus knurl is tested
Cell suspension is respectively prepared in control group and the MCF7 breast cancer cell line for striking low OSBPL2, carries out nude mice fat pad
Plantation.Every group of 6 mouse, every mouse inoculation 100 μ l, 5 × 106A cell.After 1.5 months, tumor size and volume are detected,
Carry out statistical analysis.
Fig. 3 shows the influence for striking low OSBPL2 to tumor-bearing mice growth of breast cancers.Wherein, NC is control group,
ShOSBPL2 is experimental group.As shown in figure 3, mouse-borne tumor experimental result is shown, OSBPL2 low expression group Breast Cancer tumor volume
Substantially less than control group (P < 0.05).As it can be seen that breast cancer cell growth can be significantly inhibited by reducing the expression of OSBPL2 gene.
Various embodiments of the present invention are described above, above description is exemplary, and non-exclusive, and
It is not limited to disclosed each embodiment.Without departing from the scope and spirit of illustrated each embodiment, for this skill
Many modifications and changes are obvious for the those of ordinary skill in art field.
Sequence table
<110>Jiangsu medical profession institute
<120>siRNA, recombinant vector and its application of OSBPL2 gene expression are reduced
<160> 28
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 1
gagcugcuca aacauaauga a 21
<210> 2
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 2
uucauuaugu uugagcagcu c 21
<210> 3
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 3
cacuuuaaac cguguggauu a 21
<210> 4
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 4
uaauccacac gguuuaaagu g 21
<210> 5
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 5
gggcaaaagc guggaggcgg a 21
<210> 6
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 6
uccgccucca cgcuuuugcc c 21
<210> 7
<211> 19
<212> RNA
<213> Artificial Sequence
<400> 7
uucuccgaac gugucacgu 19
<210> 8
<211> 19
<212> RNA
<213> Artificial Sequence
<400> 8
acgugacacg uucggagaa 19
<210> 9
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 9
ccgggagcug cucaaacaua augaacucga guucauuaug uuugagcagc ucuuuuug 58
<210> 10
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 10
aauucaaaaa gagcugcuca aacauaauga acucgaguuc auuauguuug agcagcuc 58
<210> 11
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 11
ccggcacuuu aaaccgugug gauuacucga guaauccaca cgguuuaaag uguuuuug 58
<210> 12
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 12
aauucaaaaa cacuuuaaac cguguggauu acucgaguaa uccacacggu uuaaagug 58
<210> 13
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 13
ccgggggcaa aagcguggag gcggacucga guccgccucc acgcuuuugc ccuuuuug 58
<210> 14
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 14
aauucaaaaa gggcaaaagc guggaggcgg acucgagucc gccuccacgc uuuugccc 58
<210> 15
<211> 57
<212> RNA
<213> Artificial Sequence
<400> 15
ccgguucucc gaacguguca cguuucaaga gaacgugaca cguucggaga auuuuug 57
<210> 16
<211> 57
<212> RNA
<213> Artificial Sequence
<400> 16
aauucaaaaa uucuccgaac gugucacguu cucuugaaac gugacacguu cggagaa 57
<210> 17
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 17
ccgggagctg ctcaaacata atgaactcga gttcattatg tttgagcagc tctttttg 58
<210> 18
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 18
aattcaaaaa gagctgctca aacataatga actcgagttc attatgtttg agcagctc 58
<210> 19
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 19
ccggcacttt aaaccgtgtg gattactcga gtaatccaca cggtttaaag tgtttttg 58
<210> 20
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 20
aattcaaaaa cactttaaac cgtgtggatt actcgagtaa tccacacggt ttaaagtg 58
<210> 21
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 21
ccgggggcaa aagcgtggag gcggactcga gtccgcctcc acgcttttgc cctttttg 58
<210> 22
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 22
aattcaaaaa gggcaaaagc gtggaggcgg actcgagtcc gcctccacgc ttttgccc 58
<210> 23
<211> 57
<212> DNA
<213> Artificial Sequence
<400> 23
ccggttctcc gaacgtgtca cgtttcaaga gaacgtgaca cgttcggaga atttttg 57
<210> 24
<211> 57
<212> DNA
<213> Artificial Sequence
<400> 24
aattcaaaaa ttctccgaac gtgtcacgtt ctcttgaaac gtgacacgtt cggagaa 57
<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 25
tgctctggag gatcaacacc 20
<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 26
gggtagaacc acctcgtctg 20
<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 27
ggcacccagc acaatgaaga 20
<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 28
actcctgctt gctgatccac 20
Claims (10)
1. a kind of siRNA, which is characterized in that the siRNA specifically reduces OSBPL2 gene expression.
2. siRNA according to claim 1, which is characterized in that the nucleotide sequence of the siRNA is included at least with next
Group nucleotide sequence:
(1) first group of nucleotide sequence
For first group of nucleotide sequence as shown in SEQ ID NO:1 and SEQ ID NO:2, the SEQ ID NO:1 is 5'-
GAGCUGCUCAAACAUAAUGAA-3', the SEQ ID NO:2 are 5'-UUCAUUAUGUUUGAGCAGCUC-3'；
(2) second groups of nucleotide sequences
For second group of nucleotide sequence as shown in SEQ ID NO:3 and SEQ ID NO:4, the SEQ ID NO:3 is 5'-
CACUUUAAACCGUGUGGAUUA-3', the SEQ ID NO:4 are 5'-UAAUCCACACGGUUUAAAGUG-3'；
(3) third group nucleotide sequence
For the third group nucleotide sequence as shown in SEQ ID NO:5 and SEQ ID NO:6, the SEQ ID NO:5 is 5'-
GGGCAAAAGCGUGGAGGCGGA-3', the SEQ ID NO:6 are 5'-UCCGCCUCCACGCUUUUGCCC-3'.
3. a kind of shRNA, which is characterized in that the nucleotide sequence of the shRNA includes at least following set of nucleotide sequence:
(1) the 5th group of nucleotide sequence
For the 5th group of nucleotide sequence as shown in SEQ ID NO:9 and SEQ ID NO:10, the SEQ ID NO:9 is 5'-
CCGGGAGCUGCUCAAACAUAAUGAACUCGAGUUCAUUAUGUUUGAGCAGCUCUUUU UG-3', the SEQ ID NO:
10 be 5'-AAUUCAAAAAGAGCUGCUCAAACAUAAUGAACUCGAGUUCAUUAUGUUUGAGC AGCUC-3'；
(2) the 6th groups of nucleotide sequences
As shown in SEQ ID NO:11 and SEQ ID NO:12, the SEQ ID NO:11 is the 6th group of nucleotide sequence
5'-CCGGCACUUUAAACCGUGUGGAUUACUCGAGUAAUCCACACGGUUUAAAGUGU UUUUG-3', the SEQ ID
NO:12 is 5'-AAUUCAAAAACACUUUAAACCGUGUGGAUUACUCGAGUAAUCCACACGGUUUA AAGUG-3'；
(3) the 7th groups of nucleotide sequences
As shown in SEQ ID NO:13 and SEQ ID NO:14, the SEQ ID NO:13 is the 7th group of nucleotide sequence
5'-CCGGGGGCAAAAGCGUGGAGGCGGACUCGAGUCCGCCUCCACGCUUUUGCCCU UUUUG-3', the SEQ ID
NO:14 is 5'-AAUUCAAAAAGGGCAAAAGCGUGGAGGCGGACUCGAGUCCGCCUCCACGCUUU UGCCC-3'.
4. encoding the DNA of shRNA as claimed in claim 3, which is characterized in that the nucleotide sequence of the DNA include at least with
Next group of nucleotide sequence:
(1) the 9th group of nucleotide sequence
As shown in SEQ ID NO:17 and SEQ ID NO:18, the SEQ ID NO:17 is the 9th group of nucleotide sequence
5'-CCGGGAGCTGCTCAAACATAATGAACTCGAGTTCATTATGTTTGAGCAGCTCT TTTTG-3', the SEQ ID
NO:18 is 5'-AATTCAAAAAGAGCTGCTCAAACATAATGAACTCGAGTTCATTATGTTTGAGC AGCTC-3'；
(2) the tenth groups of nucleotide sequences
As shown in SEQ ID NO:19 and SEQ ID NO:20, the SEQ ID NO:19 is described ten group of nucleotide sequence
5'-CCGGCACTTTAAACCGTGTGGATTACTCGAGTAATCCACACGGTTTAAAGTGT TTTTG-3', the SEQ ID
NO:20 is 5'-AATTCAAAAACACTTTAAACCGTGTGGATTACTCGAGTAATCCACACGGTTTA AAGTG-3'；
(3) the 11st groups of nucleotide sequences
As shown in SEQ ID NO:21 and SEQ ID NO:22, the SEQ ID NO:21 is the 11st group of nucleotide sequence
5'-CCGGGGGCAAAAGCGTGGAGGCGGACTCGAGTCCGCCTCCACGCTTTTGCCCT TTTTG-3', the SEQ ID
NO:22 is 5'-AATTCAAAAAGGGCAAAAGCGTGGAGGCGGACTCGAGTCCGCCTCCACGCTTT TGCCC-3'.
5. a kind of recombinant vector, which is characterized in that the recombinant vector be GV493 plasmid multiple cloning sites AgeI and
EcoRI insertion such as encodes the recombinant vector that the DNA of coding shRNA as claimed in claim 4 is obtained.
6. a kind of recombinant slow virus, which is characterized in that recombinant slow virus recombinant vector as described in claim 5 and virus
Pack helper plasmid pHelper1.0 carrier and virus packaging helper plasmid pHelper2.0 carrier cotransfection mammalian cell
It obtains.
7. a kind of host cell, which is characterized in that including siRNA of any of claims 1 or 2, as claimed in claim 3
ShRNA, the coding DNA of shRNA as claimed in claim 4, recombinant vector described in claim 5 and as claimed in claim 6
At least one of recombinant slow virus.
8. siRNA of any of claims 1 or 2, shRNA as claimed in claim 3, coding shRNA's as claimed in claim 4
At least one of recombinant vector described in DNA, claim 5 and recombinant slow virus as claimed in claim 6 inhibit in preparation
Application in the preparation of OSBPL2 gene expression.
9. siRNA of any of claims 1 or 2, shRNA as claimed in claim 3, coding shRNA's as claimed in claim 4
At least one of recombinant vector described in DNA, claim 5 and recombinant slow virus as claimed in claim 6 inhibit in preparation
Application in breast cancer cell growth and/or the drug of proliferation.
10. siRNA of any of claims 1 or 2, shRNA as claimed in claim 3, coding shRNA as claimed in claim 4
DNA, at least one of recombinant vector and recombinant slow virus as claimed in claim 6 are controlled in preparation described in claim 5
Application in the drug for the treatment of and/or prevention breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910244158.6A CN110079527B (en) | 2019-03-28 | 2019-03-28 | siRNA for reducing OSBPL2 gene expression, recombinant vector and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910244158.6A CN110079527B (en) | 2019-03-28 | 2019-03-28 | siRNA for reducing OSBPL2 gene expression, recombinant vector and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110079527A true CN110079527A (en) | 2019-08-02 |
| CN110079527B CN110079527B (en) | 2021-10-15 |
Family
ID=67413837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910244158.6A Active CN110079527B (en) | 2019-03-28 | 2019-03-28 | siRNA for reducing OSBPL2 gene expression, recombinant vector and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110079527B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160078168A1 (en) * | 2012-02-13 | 2016-03-17 | Splicingcodes.Com | Fusion transcript detection methods and fusion transcripts identified thereby |
| US20170298447A1 (en) * | 2004-05-14 | 2017-10-19 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
-
2019
- 2019-03-28 CN CN201910244158.6A patent/CN110079527B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170298447A1 (en) * | 2004-05-14 | 2017-10-19 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| US20160078168A1 (en) * | 2012-02-13 | 2016-03-17 | Splicingcodes.Com | Fusion transcript detection methods and fusion transcripts identified thereby |
Non-Patent Citations (5)
| Title |
|---|
| ARMAKOLAS A等: "Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients", 《ONCOL REP》 * |
| MARLENA S. FEJZO等: "ADRM1-amplified metastasis gene in gastric cancer", 《GENES, CHROMOSOMES AND CANCER》 * |
| 刘林林: "《恶性肿瘤生物治疗学》", 30 November 2013, 人民军医出版社 * |
| 刘静: "《分子生物学实验指导》", 31 December 2015, 中南大学出版社 * |
| 孙海燕 等: "基于高通量多组学数据分析ESYT3在乳腺癌中的表达及临床意义", 《临床检验杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110079527B (en) | 2021-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105524924B (en) | Cyclic RNA circ-ZKSCAN1 use | |
| WO2018024033A1 (en) | Cyclic rna circ-ccny and use thereof | |
| WO2018024034A1 (en) | Circular rna circ-nfatc3 and application thereof | |
| US20140302119A2 (en) | Microvesicles carrying small interfering rnas preparation methods and uses thereof | |
| CN106834290B (en) | Circular RNA and application thereof | |
| CN101869715A (en) | Cell particles carrying interfering ribonucleic acid (RNA), preparation method and application thereof | |
| CN107663539A (en) | Circular rna circ PTGR1 purposes | |
| CN111378753A (en) | Application of human PNO1 gene in lung cancer and related product | |
| CN110079527A (en) | Reduce siRNA, recombinant vector and its application of OSBPL2 gene expression | |
| CN110055249A (en) | Reduce siRNA, recombinant vector and its application of THEM6 gene expression | |
| CN109988762A (en) | Reduce siRNA, recombinant vector and its application of PSMD12 gene expression | |
| CN110117593A (en) | Specificity reduces the application of the nucleic acid, recombinant vector and recombinant slow virus of FAM84B gene expression | |
| CN109988764A (en) | Reduce siRNA, recombinant vector and its application of NKIRAS2 gene expression | |
| CN110042101A (en) | Reduce siRNA, recombinant vector and its application of ROGDI gene expression | |
| CN110129321A (en) | siRNA for reducing LSG1 gene expression, recombinant vector and application thereof | |
| WO2021037232A1 (en) | Method for editing bcl11a gene in haematopoietic stem/progenitor cells | |
| CN110144348A (en) | SiRNA, recombinant vector and its application expressed for striking low DEAH box unwindase 16 | |
| CN102056631B (en) | Apoptosis inducer | |
| CN114181936B (en) | shRNA for inhibiting chicken CA13 gene expression and application thereof | |
| CN104774872B (en) | Change the method and its application of cell fate | |
| CN116716302B (en) | Nucleic acid molecule for reducing NEK2 gene expression in esophageal cancer cells | |
| WO2022052909A1 (en) | Methods for editing bcl11a gene in hematopoietic stem/progenitor cells | |
| CN109758472B (en) | Application of circ _2157 in preparation of nasopharyngeal carcinoma treatment preparation and treatment preparation | |
| CN109908351B (en) | Application of circ _ ADARB1 in preparation of nasopharyngeal carcinoma treatment preparation and treatment preparation | |
| CN115074438A (en) | Circular RNA circTFDP2 and application of siRNA thereof in diagnosis and treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220608 Address after: No.1 Huanghai Road, Shuiji sub district office, Laixi City, Qingdao City, Shandong Province 266600 Patentee after: Qingdao Yanding Biomedical Technology Co.,Ltd. Address before: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee before: Wuxi Xiangyuan Information Technology Co.,Ltd. Effective date of registration: 20220608 Address after: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi Xiangyuan Information Technology Co.,Ltd. Address before: 224008 no.283, Jiefang South Road, Yancheng City, Jiangsu Province Patentee before: JIANGSU VOCATIONAL College OF MEDICINE |